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Local recurrence in lung cancer and glioblastoma multiforme is 
a persistent problem despite recent advancements in therapeutic 
regimens that have improved tumor response (1–4). These tumor 
types are highly angiogenic and resistant to radiation (5,6). Despite 
aggressive treatment, most patients with unresectable glioblastoma 
multiforme have a median survival of approximately 1 year (2,7,8). 
Patients with unresectable non–small cell lung cancer have a simi-
larly poor prognosis (9–12). Additional treatments are therefore 
needed to provide improved survival benefits for these patients (13).
Understanding how the tumor microenvironment responds to 
therapeutic intervention is important for developing efficient mo-
lecular targeted pharmacological agents (14–16). We have recently 
demonstrated that activation of cytosolic phospholipase A2 (cPLA2), 
an enzyme involved in the formation of lipid second messengers, 
stimulates proliferation of vascular endothelial cells and promotes 
the formation of a functional tumor vascular network, thereby 
contributing to cancer progression (17,18). Upon activation, cPLA2 
translocates from the cytosol to cell membranes (19,20), where 
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  Background  Lung cancer and glioblastoma multiforme are highly angiogenic and, despite advances in treatment, remain 
resistant to therapy. Cytosolic phospholipase A2 (cPLA2) activation contributes to treatment resistance through 
transduction of prosurvival signals. We investigated cPLA2 as a novel molecular target for antiangiogenesis 
therapy.
  Methods  Glioblastoma (GL261) and Lewis lung carcinoma (LLC) heterotopic tumor models were used to study the effects 
of cPLA2 expression on tumor growth and vascularity in C57/BL6 mice wild type for (cPLA2a1/1) or deficient in 
(cPLA2a2/2) cPLA2a, the predominant isoform in endothelium (n = 6–7 mice per group). The effect of inhibiting 
cPLA2 activity on GL261 and LLC tumor growth was studied in mice treated with the chemical cPLA2 inhibitor 
4-[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]-ethoxy]benzoic acid (CDIBA). Endothelial cell prolifera-
tion and function were evaluated by Ki-67 immunofluorescence and migration assays in primary cultures of 
murine  pulmonary  microvascular  endothelial  cells  (MPMEC)  isolated  from  cPLA2a1/1  and  cPLA2a2/2  mice. 
Proliferation, invasive migration, and tubule formation were assayed in mouse vascular endothelial 3B-11 cells 
treated with CDIBA. Effects of lysophosphatidylcholine, arachidonic acid, and lysophosphatidic acid (lipid medi-
ators of tumorigenesis and angiogenesis) on proliferation and migration were examined in 3B-11 cells and 
cPLA2a2/2 MPMEC. All statistical tests were two-sided.
  Results  GL261 tumor progression proceeded normally in cPLA2a1/1 mice, whereas no GL261 tumors formed in cPLA2a2/2 
mice.  In  the  LLC  tumor  model,  spontaneous  tumor  regression  was  observed  in  50%  of  cPLA2a2/2  mice. 
Immunohistochemical examination of the remaining tumors from cPLA2a2/2 mice revealed attenuated vascu-
larity (P ≤ .001) compared with tumors from cPLA2a1/1 mice. Inhibition of cPLA2 activity by CDIBA resulted in a 
delay in tumor growth (eg, LLC model: average number of days to reach tumor volume of 700 mm3, CDIBA vs 
vehicle: 16.8 vs 11.8, difference = 5, 95% confidence interval = 3.6 to 6.4, P = .04) and a decrease in tumor size 
(eg, GL261 model: mean volume on day 21, CDIBA vs vehicle: 40.1 vs 247.4 mm3, difference = 207.3 mm3, 95% 
confidence interval = 20.9 to 293.7 mm3, P = .021). cPLA2 deficiency statistically significantly reduced MPMEC 
proliferation  and  invasive  migration  (P  =  .002  and  P  =  .004,  respectively).  Compared  with  untreated  cells, 
cPLA2a
2/2 MPMEC treated with lysophosphatidylcholine and lysophosphatidic acid displayed increased cell pro-
liferation (P = .011) and invasive migration (P < .001).
  Conclusions  In these mouse models of brain and lung cancer, cPLA2 and lysophospholipids have key regulatory roles in 
tumor angiogenesis. cPLA2 inhibition may be a novel effective antiangiogenic therapy.
      J Natl Cancer Inst 2010;102:1398–1412jnci.oxfordjournals.org    JNCI | Articles 1399
purchased from Avanti Polar Lipids (Alabaster, AL). All lipids 
were dissolved in 70% ethanol according to the manufacturers’ 
instructions.
Cell Cultures and Treatment
Murine Lewis lung carcinoma (LLC) cells and murine vascular 
endothelial  3B-11  cells  were  purchased  from  American  Type 
Culture Collection (Manassas, VA). Mouse glioblastoma GL261 
cells  were  obtained  from  Dr  Yancie  Gillespie  (University  of 
Alabama-Birmingham, Birmingham, AL). The identity of each cell 
line was verified by immunostaining for specific markers. 3B-11, 
LLC, and GL261 cells were maintained in Dulbecco’s modified 
Eagle medium containing 10% fetal bovine serum and 1% penicillin–
streptomycin (Life Technologies, Gaithersburg, MD) at 37°C and 
in 5% CO2. Human umbilical vein endothelial cells (HUVEC) 
were obtained from Cambrex (East Rutherford, NJ) and were 
maintained  in  microvascular  endothelial  cell  growth  medium-2 
it specifically cleaves phosphatidylcholine (21–24) to produce the 
bioactive  lipids  lysophosphatidylcholine  and  arachidonic  acid 
(17,18). In addition to these lipids, which are involved in vascular 
signaling and tumor progression, lysophosphatidic acid is another 
cPLA2-derived lipid signaling molecule with known tumorigenic 
and angiogenic properties (25–27). The major pathways of lyso-
phosphatidic acid production depend on cPLA2 activity: 1) lyso-
phospholipids generated by cPLA2 (such as lysophosphatidylcholine) 
are subsequently converted to lysophosphatidic acid by lysophos-
pholipase D and 2) phosphatidic acid generated by phospholipase 
D or diacylglycerol kinase is subsequently converted to lysophos-
phatidic acid by cPLA2 (28,29). Therefore, cPLA2 is involved in 
regulating  the  levels  of  at  least  three  potent  lipid  mediators  of   
tumorigenesis and angiogenesis: lysophosphatidylcholine, arachi-
donic acid, and lysophosphatidic acid. The role of arachidonic acid 
and lysophosphatidic acid in tumorigenesis has been studied exten-
sively. There is a broad literature linking these two lipids, their 
turnover, and signaling to cancer progression (24,30–32). There 
has been active discussion (33,34) regarding the use of arachidonic 
acid  and  lysophosphatidic  acid  signaling  pathways  as  molecular 
targets for controlling cancer, and several companies are devel-
oping drugs for this purpose. By contrast, relatively little is known 
about the role of lysophosphatidylcholine in tumor progression. 
Recent studies by our laboratory and others (17,18,35) have shown 
that lysophosphatidylcholine is a lipid-derived second messenger 
that triggers the downstream activation of both phosphatidylinositol 
3-kinase/Akt  and  mitogen-activated  protein  kinase/extracellular 
signal regulated kinase prosurvival signal transduction pathways, 
resulting  in  increased  cell  viability  within  the  tumor  vascular 
endothelium.
To investigate the effects of cPLA2 and cPLA2-dependent lyso-
phosphatidylcholine production, as well as the roles of arachidonic 
acid and lysophosphatidic acid, on the growth of lung carcinoma and 
glioblastoma, we used cPLA2a
2/2 C57/BL6 mice, which are defi-
cient in cPLA2a, the predominant isoform of cPLA2 in endothelium, 
to examine the effect of a deficiency in cPLA2 in the host-derived 
vascular endothelium on tumor maintenance and progression. 
In addition, we used murine pulmonary microvascular endothelial 
cells (MPMEC) isolated from from cPLA2a
2/2 mice to investigate 
the effects of lysophosphatidylcholine, lysophosphatidic acid, and 
arachidonic acid on cell viability and functions. To further inhibit 
cPLA2 in cell culture models and in wild-type mice, we used a 
chemical  inhibitor  of  cPLA2a  known  as  4-[2-[5-chloro-1-
(diphenylmethyl)-2-methyl-1H-indol-3-yl]-ethoxy]benzoic  acid 
(CDIBA), which has been shown to substantially attenuate arachi-
donic acid release and prostaglandin E2 production in a wide variety 
of enzymatic and cell-based assays (36).
Materials and Methods
Chemicals
CDIBA  was  synthesized  by  the  Chemical  Synthesis  Core 
Facility of Vanderbilt University (97% purity by nuclear magnetic 
resonance–mass spectrometry). CDIBA was dissolved in dimethyl 
sulfoxide  (DMSO).  l-a-Lysophosphatidylcholine  and  arachi-
donic acid were purchased from Sigma–Aldrich (St Louis, MO). 
Lysophosphatidic acid (18 [carbon atoms]:1 [double bond]) was 
CONTEXT AND CAVEATS
Prior knowledge
Two  highly  angiogenic  malignancies—lung  cancer  and  glioblas-
toma multiforme—remain resistant to existing therapies. Activation 
of cytosolic phospholipase A2 (cPLA2), an enzyme that catalyzes 
the  formation  of  bioactive  lipids  involved  in  tumorigenesis  and 
angiogenesis, contributes to treatment resistance through trans-
duction of prosurvival signals.
Study design
The effects of cPLA2 expression on glioblastoma and lung tumor 
growth and vascularity were studied in mice wild type (cPLA2a
1/1) 
and deficient (cPLA2a
2/2) in cPLA2a (the predominant isoform of the 
enzyme) and in mice injected intraperitoneally with the chemical 
cPLA2 inhibitor CDIBA. Mouse vascular endothelial 3B-11 cells and 
murine pulmonary microvascular endothelial cells (MPMEC) iso-
lated from cPLA2a
1/1 and cPLA2a
2/2 mice were used to study cell 
proliferation and function and the effects of lipid mediators of tu-
morigenesis and angiogenesis on proliferation and migration.
Contribution
cPLA2a2/2  mice  formed  fewer  tumors  compared  with  cPLA2a1/1 
mice.  Tumors  from  cPLA2a2/2  mice  displayed  attenuated  vascu-
larity compared with tumors from cPLA2a1/1 mice. Inhibition of 
cPLA2 activity by CDIBA in cPLA2a1/1 mice resulted in a delay in 
tumor growth and a decrease in tumor size. cPLA2 deficiency or 
inhibition  with  CDIBA  statistically  significantly  reduced  MPMEC 
proliferation  and  invasive  migration.  Compared  with  untreated 
cells, cPLA2a2/2 MPMEC treated with lysophosphatidylcholine and 
lysophosphatidic  acid  displayed  increased  cell  proliferation  and 
invasive migration.
Implications
cPLA2 inhibition may be a novel effective antiangiogenic therapy in 
patients with glioblastoma multiforme and lung cancer.
Limitations
The heterotopic mouse models that were used to study the effect 
of cPLA2 on tumor growth may not accurately reflect the original 
tumor organ site.
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(EGM-2-MV; Cambrex). Cells were treated with vehicle (DMSO) 
or 2 µM CDIBA in the absence or presence of 10 µM lysophospha-
tidylcholine, 10 µM lysophosphatidic acid, or 10 µM arachidonic 
acid for the indicated times before each assay. Cells were treated 
without induction of serum starvation because it introduces vari-
ability and additional stress to the endothelial cell culture systems. 
Therefore, cells were treated in the same medium in which they 
had been growing for 2–3 days before treatment.
Isolation of MPMEC
Primary cultures of MPMEC were isolated from 1- to 3-month-
old cPLA2 wild-type (cPLA2a
1/1) or knockout (cPLA2a
2/2) C57/BL6 
mice (kindly provided by Dr J. V. Bonventre, Renal Unit, Brigham 
Women’s  Hospital,  Harvard  Medical  School,  Boston,  MA). 
cPLA2a
1/1 and cPLA2a
2/2 mice (four of each type) were anesthe-
tized with isoflurane. The lung vasculature was perfused via the 
right ventricle with phosphate-buffered saline and 2 mM EDTA 
followed by 0.25% trypsin and 2 mM EDTA. The heart and lungs 
were excised and incubated in a sterile environment at 37°C for 20 
minutes. The visceral pleura were removed, and the perfusion was 
repeated.  The  resulting  cellular  suspension  was  collected  and 
plated onto tissue culture plates coated with 0.2% gelatin in EGM-
2-MV containing 5% fetal bovine serum to enrich for endothelial 
cells. After several weeks of propagation at 37°C, the proportion of 
endothelial cells in the cultures was evaluated by immunostaining 
with  a  rabbit  polyclonal  antibody  against  the  endothelial  cell 
marker  von  Willebrand  factor  (vWF)  (1:100  dilution;  Dako, 
Carpinteria, CA). Staining was detected by immunofluorescence 
with Alexa Fluor 488–conjugated goat anti-rabbit IgG (1:500 dilu-
tion; Invitrogen Molecular Probes, Carlsbad, CA) for 1 hour at 
room temperature, and cultures with endothelial cell purity greater 
than 95% were used in proliferation and migration experiments. 
We followed protocols approved by the Institutional Animal Care 
and Use Committee of Vanderbilt University when handling and 
treating all mice used in this study (approved protocol M/04/013).
Matrigel-Based Tubule Formation Assay
The ability of 3B-11 and HUVEC to form capillary-like tubules 
was analyzed in 24-well plates coated with Matrigel (300 µL per 
well;  BD  Biosciences,  Bedford,  MA)  for  30  minutes  at  37°C. 
3B-11 or HUVEC (10 000 cells per well) were plated onto solidi-
fied Matrigel, which simulates the basement membrane matrix, 
and allowed to attach for 30 minutes before treatment with vehicle 
(control) or 2 µM CDIBA. The wells were periodically monitored 
for tubule formation by light microscopy. Tubules formed in con-
trol cells at 6 (3B-11) and 24 (HUVEC) hours after treatment. 
Following tubule formation, digital micrographs of all wells were 
obtained using an inverted light microscope at ×20 and ×40 mag-
nification. Tubules from four randomly selected ×40 high-power 
fields (HPFs) per sample were counted, and results are presented 
as the average number of tubules per HPF. Samples were assayed 
in triplicate from three independent experiments.
Scratch Assay for Cell Migration
3B-11 or LLC cells were grown to 70%–80% confluency in 60 × 
15 mm cell culture dishes. Four parallel wounds were created on 
each plate by scratching the cell monolayer with a 10-µL pipette 
tip, and boundaries of the wounds were marked. Cells were treated 
for 24 hours with vehicle or 2 µM CDIBA. The cells were then 
stained with 1% methylene blue, and cells found inside and outside 
of the wound boundaries were counted from six HPFs per sample. 
Cells that spanned the boundaries were classified as non-migrated 
cells. Cell density within the wound is presented as a percentage of 
total cell density in the plate. Results are from triplicate samples in 
three independent scratch assays.
Boyden Chamber Transwell Invasion and Migration Assay
3B-11 (50 000 cells per well) or MPMEC (80 000 cells per well) 
were  added  to  the  top  chamber  of  24-well  plates  containing 
Matrigel-coated  transwell  insert  filters  (8-µm  pore  size;  Costar 
Corning, Corning, NY). Fresh medium (600 µL) was added to the 
bottom chamber, and the cells were incubated for 30 minutes to 
allow attachment to the inserts. Both chambers were then treated 
with vehicle or 2 µM CDIBA (3B-11 cells only) in the absence or 
presence of 10 µM lysophosphatidylcholine, 10 µM lysophospha-
tidic acid, or 10 µM arachidonic acid. The cells were incubated for 
24 hours at 37°C in 5% CO2. All cells on the upper surface of the 
transwell insert filter were removed with a cotton swab. The insert 
filters  were  rinsed  in  phosphate-buffered  saline,  fixed  in  100% 
methanol, and stained with 4′,6-diamidino-2-phenylindole (DAPI; 
2.5 ng/µL). Cells that had migrated through the filter (ie, those on 
the lower surface of the filter) were photographed with the use of 
a Zeiss fluorescent microscope and counted for four randomly se-
lected HPFs from each sample. The average number of migrated 
cells per HPF was calculated for three independent experiments.
Cell Proliferation Assays
Ki-67 Immunofluorescence Staining.  3B-11, MPMEC, or LLC 
cells were grown to 60%–70% confluency on slides. Cultures were 
treated with vehicle or 2 µM CDIBA (3B-11 and LLC cells only) 
for 24 hours in the absence or presence of 10 µM lysophosphati-
dylcholine, 10 µM lysophosphatidic acid, or 10 µM arachidonic 
acid. The cells were fixed in ice-cold methanol and permeabilized 
in  0.25%  Triton  X-100  for  10  minutes  at  room  temperature. 
Following permeabilization, the cells were incubated overnight at 
4°C with a rabbit polyclonal antibody against Ki-67 (1:100 dilu-
tion; Abcam, Inc, Cambridge, MA) followed by incubation with 
Alexa Fluor 488–conjugated goat anti-rabbit IgG (1:500 dilution; 
Invitrogen Molecular Probes) for 1 hour at room temperature. 
The cells were counterstained with DAPI (2.5 ng/µL), and Ki-67–
positive cells were detected by immunofluorescence microscopy 
and counted in four randomly selected HPFs per sample. Positive 
cells were classified as those in which nuclear fluorescence was 
present, and KI-67–negative cells were those in which no nuclear 
fluorescence  was  detected.  Samples  were  analyzed  in  triplicate 
from  three  independent  experiments,  and  Ki-67–positive  cells 
were presented as a percentage of the number of Ki-67–positive 
cells in vehicle-treated control cells.
5-Bromodeoxyuridine Incorporation.  3B-11 cells were plated in 
96-well plates (5000 cells per well) and incubated for 24 hours. The 
cells were treated with vehicle or 2 µM CDIBA for 24 or 72 hours in 
the absence or presence of 10 µM lysophosphatidylcholine, 10 µM jnci.oxfordjournals.org    JNCI | Articles 1401
lysophosphatidic acid, or 10 µM arachidonic acid. Incorporation of 
5-bromodeoxyuridine (BrdU) was measured in each well with the 
use of an enzyme-linked immunosorbent assay–based 5-Bromo-2′-
deoxy-uridine  Labeling  and  Detection  Kit  III  (Roche  Applied 
Science, Indianapolis, IN) according to the manufacturer’s instruc-
tions. BrdU incorporation was quantified by a change of absor-
bance  (optical  density)  at  405  nm.  Samples  were  analyzed  in 
triplicate from three independent experiments.
MTS Assay for Metabolic Activity
3B-11 cells were plated in 96-well plates (5000 cells per well) and 
allowed to attach for 24 hours. Cultures were treated with vehicle 
or 2 µM CDIBA for 24 or 72 hours in the absence or presence of 
10 µM lysophosphatidylcholine, 10 µM lysophosphatidic acid, or 
10 µM arachidonic acid. Metabolic activity was analyzed by a form 
of the 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay using a 
CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit 
(Promega, Madison, WI) according to the manufacturer’s instruc-
tions.  Metabolic  activity  was  expressed  as  absorbance  (optical 
density) at 490 nm and was assessed from triplicate samples in 
three independent experiments.
Mouse Tumor Models, Treatments, and Tumor Growth 
Delay Studies
We followed protocols approved by the Institutional Animal Care 
and Use Committee of Vanderbilt University when handling and 
treating all mice used in this study (approved protocols M/04/013 
and M/07/358).
We used C57/BL6 cPLA2a
1/1 and cPLA2a
2/2 mice (provided 
by Dr J. V. Bonventre). The cPLA2a
2/2 mouse was created by 
disruption  of  an  exon  containing  Ser228,  which  is  critical  for 
cPLA2a catalytic activity, in mouse embryonic stem cells (37). The 
homozygous  null  mice  experience  normal  development,  weight 
gain, and life spans and do not exhibit any spontaneous tumor 
formation. As expected, cPLA2a
2/2 mice have reduced levels of 
eicosanoid production (37).
For tumor growth studies in cPLA2a-deficient mice, LLC (10
6) or 
GL261 (2 × 10
6) cells were injected subcutaneously into the right hind 
limbs of cPLA2a
1/1 and cPLA2a
2/2 mice (n = 6–7 mice per group). 
The volumes of the resulting tumors were measured at 48-hour 
intervals using power Doppler sonography as described below.
For tumor growth delay studies in mice treated with CDIBA, 
LLC (10
6) or GL261 (2 × 10
6) cells were implanted into the right 
hind limbs of cPLA2a
1/1 C57/BL6 mice. Once, all tumors exceeded 
2 mm in diameter (approximately 2 weeks later), as determined by 
external caliper measurements, the mice were stratified into groups 
of six to seven animals representing similar distributions of tumor 
sizes (range = 3–5 mm in diameter). LLC tumor–bearing mice 
were injected intraperitoneally with vehicle (DMSO) or CDIBA at 
0.5 or 1.0 mg per kg body weight once daily for five consecutive 
days.  GL261  tumor–bearing  mice  were  treated  with  vehicle  or 
CDIBA at 1.0 mg per kg body weight once daily for seven consec-
utive days. Tumor size was monitored by external caliper measure-
ments at 48-hour intervals. Mice were killed by cervical dislocation 
once  tumors  reached  a  volume  of  approximately  700  mm
3  or 
exceeded 15 mm in diameter, per Animal Care guidelines.
Power Doppler Sonography
Tumors were sonographically imaged with a VEVO 770 small-
animal  high-resolution  ultrasound  scanner  equipped  with  a 
40-MHz transducer and a mechanically scanned single-element 
aperture (VisualSonics, Toronto, ON, Canada). The focal zone of 
the transducer was set at 6 mm from the scanning surface. The 
scanning plane was perpendicular to the long axis of the lower 
extremity along the entire length of the tumor. Three-dimensional 
images in power Doppler mode were obtained by computer-
controlled translation of the transducer over the whole length of 
the tumor by acquiring two-dimensional images every 100 µm. The 
following ultrasound scanner settings were used: a power Doppler 
transmission frequency of 23 MHz, a power gain of 100%, a wall 
filter of 2.3 mm/s, and a scan speed of 2.0 mm/s. Three-dimensional 
tumor  volume  was  reconstructed  by  using  semiautomated  seg-
mentation of 10–12 parallel planes through the two-dimensional 
images with the use of VisualSonics image analysis software.
Assessment of cPLA2 Activity and Lysophosphatidic Acid 
Concentration in Plasma From Tumor-Bearing Mice
Vehicle or CDIBA at 1.0 mg per kg body weight was intraperito-
neally  injected  once  daily  for  five  consecutive  days  into  LLC 
tumor–bearing cPLA2a
1/1 mice (five mice per group). Mice were 
anesthetized with ketamine/xylazine, and blood samples were col-
lected  from  the  tail  veins  immediately  before  the  initiation  of 
treatment and 1 hour after the final treatment. Blood samples were 
immediately processed for plasma isolation and stored at 280°C. 
cPLA2 activity in thawed plasma samples was analyzed by using a 
cPLA2 activity kit (Cayman Chemical, Ann Arbor, MI) according 
to the manufacturer’s instructions. Briefly, thawed plasma samples 
were incubated with 1.5 mM arachidonoyl thio-phosphotidylcho-
line (a cPLA2 substrate) for 1 hour at room temperature. Enzyme 
catalysis was stopped by the addition of beta dystrobrevin/EGTA, 
and the optical density of the sample was measured at 405 nm. 
cPLA2 activity was expressed in micromoles per minute per milliliter. 
Lysophosphatidic acid concentration was assessed by a competitive 
enzyme-linked  immunosorbent  assay  (Echelon  Biosciences,  Inc, 
Salt Lake City, UT) according to the manufacturer’s instructions 
and was expressed in micromoles.
Histological Analysis of Tumor Vascularity
In  the  tumor  growth  delay  studies,  once  LLC  tumors  from 
cPLA2a
1/1 and cPLA2a
2/2 mice reached a volume of approximately 
700  mm
3,  the  mice  were  killed  by  cervical  dislocation  and  the 
tumors  were  resected,  fixed  in  10%  formalin,  and  sectioned. 
Sections (5 µm thick) underwent antigen retrieval by pretreatment 
with 20 µg/mL proteinase K for 30 minutes at room temperature 
and then were incubated with a rabbit polyclonal antibody against 
human vWF (1:100 dilution; Dako). Sections were subsequently 
incubated with Alexa Fluor 488–conjugated goat anti-rabbit IgG 
(1:500 dilution; Invitrogen Molecular Probes) for 1 hour at room 
temperature.  Sections  were  studied  by  immunofluorescence 
microscopy, and the Alexa Fluor 488–stained vessels were counted 
in six randomly selected HPFs per sample. Vascularity was deter-
mined as the average number of stained vessels per HPF. Tissue 
integrity was assessed by standard hematoxylin–eosin staining and 
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Co-staining of Mouse Tumors for vWF and Alpha-Smooth 
Muscle Actin or Desmin
Slides containing formalin-fixed LLC tumor sections (5 µm thick) 
were incubated with 20 µg/mL proteinase K as described above, 
followed by incubation for 1 hour at room temperature with   
the mouse immunoglobulin blocking reagent from a M.O.M. 
Immunodetection  Kit  (Vector  Laboratories,  Burlingame,  CA). 
Sections were then incubated at 4°C overnight with rabbit poly-
clonal anti-human vWF antibody and either a monoclonal mouse 
anti-human a-smooth muscle actin (a-SMA) antibody or a mono-
clonal mouse anti-human desmin antibody (all at 1:100 dilution; 
Dako). The slides were rinsed in phosphate-buffered saline, and 
the sections were incubated with DAPI (1:1000 dilution), Alexa 
Fluor  594–conjugated  goat  anti-mouse  IgG  (1:200  dilution; 
Invitrogen  Molecular  Probes),  and  Alexa  Fluor  488–conjugated 
goat anti-rabbit IgG (1:500 dilution; Invitrogen Molecular Probes) 
for 1 hour at room temperature. Positive staining was determined 
by immunofluorescence microscopy.
Statistical Analysis
The Student t test or the Mann–Whitney rank sum test was used 
to  compare  two  groups  and  one-way  analysis  of  variance  and 
Holm–Sidak  multiple-group  posttest  comparisons  was  used  for 
comparisons among multiple groups. All statistical tests were 
two-sided, and the statistical analysis was done with the use of 
SigmaStat  software  (Systat  Software,  Inc,  San  Jose,  CA). 
Longitudinal analysis was performed on serial tumor volume data. 
Statistical significance was defined as P less than .05. Data are pre-
sented as mean values with 95% confidence intervals (CIs).
Results
Effect  of  Lysophospholipids  on  Proliferation  of  cPLA2-
Deficient and CDIBA-Treated Mouse Vascular Endothelial 
Cells
Because new blood vessel formation requires vascular endothelial 
cell  proliferation,  we  used  primary  MPMEC  isolated  from 
cPLA2a
1/1 or cPLA2a
2/2 mice to assess the effects of cPLA2 defi-
ciency  on  cell  growth  and  proliferation.  MPMEC  were  first 
stained with an antibody to Ki-67, an established cell proliferation 
marker. Ki-67 staining in cPLA2a
2/2 cells was reduced to 41.4% 
(95% CI = 16.5% to 66.3%, P = .002) compared with cPLA2a
1/1 
cells (Figure 1, A). Further evidence that cPLA2 supports endothe-
lial cell proliferation resulted from Ki-67 immunostaining of LLC 
lung tumor cells and vascular endothelial 3B-11 cells that were 
treated with the cPLA2 inhibitor, CDIBA (2 µM), or vehicle. The 
number of Ki-67–positive 3B-11 cells treated with CDIBA was 
reduced to 43.8% (95% CI = 27.0% to 60.6%, P < .001) compared 
Figure 1. Effect of lysophospholipids on prolif-
eration  of  cPLA2-deficient  and  CDIBA-treated 
vascular endothelial cells. cPLA2a1/1 (wild-type 
[WT])  and  cPLA2a2/2  (knockout  [KO])  murine 
pulmonary microvascular endothelial cells (A), 
murine vascular endothelial 3B-11 cells (B,C), 
or Lewis lung carcinoma (LLC) cells (C) were 
grown to 60%–70% confluency. Cultures were 
treated with vehicle (control) or 2 µM CDIBA 
(3B-11 and LLC only) in the absence or pres-
ence of 10 µM lysophosphatidylcholine (LPC), 
10 µM lysophosphatidic acid (LPA), or 10 µM 
arachidonic acid (AA) for 24 hours. Proliferation 
was assayed by staining the cells with an anti-
body  against  Ki-67  and  immunofluorescence 
microscopy.  The  number  of  Ki-67–positive 
cells  was  counted  in  four  randomly  selected 
high-power  microscopic  fields  from  each 
sample  in  triplicate  and  is  expressed  as  the 
mean  percentage  of  the  number  of  Ki-67–
positive  cells  in  the  control  sample  in  three 
independent  experiments;  error  bars  corre-
spond  to  95%  confidence  intervals.  A):  *P  = 
.002  (Student  t  test);  **P  =  .011  (analysis  of 
variance  [ANOVA]).  B):  *P  <  .001  (Mann–
Whitney rank sum test); **P = .001 (ANOVA). 
C): *P = .004 (Student t test). All P values are 
two-sided.
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with 3B-11 cells treated with vehicle alone (Figure 1, B). By con-
trast, inhibition of cPLA2 by CDIBA had no statistically significant 
effect on the percentage of Ki-67–positive LLC tumor cells com-
pared with LLC cells treated with vehicle alone (91.8% [CDIBA] 
vs 100% [vehicle], difference = 8.2%, 95% CI = 26.6% to 23.2%, 
P = .464) (Figure 1, C).
By using a more direct assay of cellular proliferation, we found 
that BrdU incorporation was reduced by 50% (95% CI = 15.4% to 
85.6%, P = .03) in 3B-11 cells treated with CDIBA compared 
with control cells treated with vehicle alone (data not shown). 
Conversely, an MTS assay for metabolic activity revealed no sta-
tistically significant difference between CDIBA-treated 3B-11 cells 
and 3B-11 cells treated with vehicle alone (data not shown), sug-
gesting that cPLA2 inhibition affects the proliferative status but 
not the metabolic processes of vascular endothelial cells.
cPLA2 is essential for the production of three bioactive lipid 
mediators:  arachidonic  acid,  lysophosphatidylcholine,  and  lyso-
phosphatidic acid (24,27). To examine whether any of these three 
lipids contribute to vascular endothelial cell proliferation, we incu-
bated MPMEC from cPLA2a
2/2 and CDIBA-treated 3B-11 cells 
with 10 µM lysophosphatidylcholine, 10 µM lysophosphatidic acid, 
or 10 µM arachidonic acid for 24 hours and then assessed the cells 
for Ki-67 staining. Compared with untreated cPLA2a
2/2 MPMEC, 
treatment of cPLA2a
2/2 MPMEC with lysophosphatidylcholine or 
lysophosphatidic  acid  alone  did  not  substantially  increase  the 
number of Ki-67–positive cells. However, the number of Ki-67–
positive  cells  (expressed  as  a  percentage  of  that  in  untreated 
cPLA2a
1/1  MPMEC)  was  statistically  significantly  higher  in 
cPLA2a
2/2 MPMEC treated with the combination of lysophospha-
tidylcholine and lysophosphatidic acid compared with untreated 
cPLA2a
2/2 MPMEC (treated vs control: 75% vs 41.4%, difference = 
33.6%, 95% CI = 18.3% to 49.7%, P = .011) (Figure 1, A). 
Treatment  of  cPLA2a
2/2  MPMEC  with  exogenous  arachidonic 
acid, alone, or in combination with lysophosphatidylcholine con-
tributed little to Ki-67 immunofluorescence (Figure 1, A). This 
latter  combination—lysophosphatidylcholine  plus  arachidonic 
acid—served  as  a  negative  control  for  the  observed  effect  of 
lysophosphatidylcholine  plus  lysophosphatidic  acid  because  it 
accounted for the potential effects of the addition of ethanol (the 
diluent) and lipid contaminents in ethanol. Treatment of 3B-11 
cells with CDIBA and lysophosphatidylcholine or lysophospha-
tidic acid resulted in slight increases in the number of Ki-67–
positive cells compared with cells treated with CDIBA alone (56% 
vs 44% and 58% vs 44%, respectively; Figure 1, B). Treatment of 
3B-11 cells with CDIBA and arachidonic acid also resulted in a 
slight increase in the number of Ki-67–positive cells compared 
with cells treated with CDIBA alone (56% vs 44%; Figure 1, B). 
Combined  treatment  with  lysophosphatidylcholine  and  arachi-
donic acid further increased the number of Ki-67–positive cells to 
62% (Figure 1, B). However, only 3B-11 cells treated with CDIBA 
and the combination of lysophosphatidylcholine and lysophospha-
tidic acid had a statistically significant increase in the number   
of  Ki-67–positive  cells  compared  with  3B-11  cells  treated  with 
CDIBA alone (CDIBA+ lysophosphatidylcholine + lysophospha-
tidic acid vs CDIBA: 81% vs 44%, difference = 37%, 95% CI = 
34.1%  to  41.6%,  P  =  .001)  (Figure  1,  B).  Similar  results  were 
obtained using the BrdU incorporation assay, in which the addition 
of exogenous lysophosphatidylcholine and lysophosphatidic acid 
to CDIBA-treated 3B-11 cells resulted in increased BrdU incorpo-
ration compared with cells treated with CDIBA alone (data not 
shown). Thus, these results indicate that in addition to arachidonic 
acid,  both  cPLA2-dependent  lysophosphatidylcholine  and  lyso-
phosphatidic  acid  may  be  involved  in  vascular  endothelial  cell 
proliferation.
Effect of Lysophospholipids on Invasion and Migration of 
cPLA2-Deficient and CDIBA-Treated Vascular Endothelial 
Cells
Blood vessel formation requires degradation of the extracellular 
matrix  and  invasion  of  adjacent  tissues  by  endothelial  cells. 
Therefore, we next examined the effect of lysophospholipids on 
endothelial cell invasion and migration. cPLA2a
2/2 or cPLA2a
1/1 
MPMEC or 3B-11 cells were plated onto Matrigel-coated tran-
swell filter inserts and treated for 24 hours with vehicle or with 
2 µM CDIBA in absence or presence of 10 µM lysophosphatidyl-
choline, 10 µM lysophosphatidic acid, or 10 µM arachidonic acid. 
Cells that had migrated through filters were stained with DAPI 
and counted with the use of fluorescence microscopy. The mean 
number of migrated cells per HPF was 78% lower in cPLA2a
2/2 
MPMEC  compared  with  cPLA2a
1/1  MPMEC  (cPLA2a
2/2  vs 
cPLA2a
1/1: 9.3 vs 46.4 migrated cells per HPF, difference = 37.1 
migrated cells per HPF, 95% CI = 17.2 to 57.0 migrated cells per 
HPF, P = .004) (Figure 2, A). Treatment of cPLA2a
2/2 MPMEC 
with lysophosphatidylcholine plus arachidonic acid produced only 
a slight increase in the mean number of migrated cells compared 
with untreated cPLA2a
2/2 MPMEC, whereas treatment with lyso-
phosphatidylcholine plus lysophosphatidic acid produced a statis-
tically significant increase in the mean number of migrated cells 
(cPLA2a
2/2  MPMEC  +  lysophosphatidylcholine  +  lysophospha-
tidic acid vs untreated cPLA2a
2/2 MPMEC: 33.5 vs 9.3 migrated 
cells per HPF, difference = 23.3 migrated cells per HPF, 95% CI = 
3.9 to 42.6 migrated cells per HPF, P < .001) (Figure 2, A).
Treatment of 3B-11 cells with CDIBA alone reduced the mean 
number of migrated cells per HPF by 71% compared with vehicle-
treated control cells (CDIBA vs control: 10.3 vs 34.9 migrated cells 
per HPF, difference = 24.6 migrated cells per HPF, 95% CI = 17.8 
to  31.7  migrated  cells  per  HPF,  P  <  .001)  (Figure  2,  B).  As 
expected, treatment of 3B-11 cells with CDIBA and arachidonic 
acid, a known stimulator of cell migration (38,39), increased the 
mean number of migrated cells per HPF by 58% compared with 
cells  treated  with  CDIBA  alone  (CDIBA  +  arachidonic  acid  vs 
CDIBA: 23.6 vs 10.3 migrated cells per HPF, difference = 13.3 
migrated cells per HPF, 95% CI = 11.6 to 15.3 migrated cells per 
HPF, P < .001) (Figure 2, B). We observed a similar increase in the 
mean number of migrated cells per HPF in 3B-11 cells treated 
with CDIBA and either lysophosphatidylcholine or lysophospha-
tidic acid compared with 3B-11 cells treated with CDIBA alone (24 
[CDIBA + lysophosphatidylcholine] or 21.1 [CDIBA + lysophos-
phatidic acid] vs 10.3 [CDIBA] migrated cells per HPF, respec-
tively; Figure 2, B). However, compared with 3B-11 cells treated 
with CDIBA alone, the most pronounced increase in the number 
of migrated cells was for 3B-11 cells that were treated with CDIBA 
and either lysophosphatidylcholine plus lysophosphatidic acid 
(CDIBA + lysophosphatidylcholine + lysophosphatidic acid vs 1404   Articles | JNCI  Vol. 102, Issue 18  |  September 22, 2010
CDIBA: 30.5 vs 10.3 migrated cells per HPF, difference = 20.2 
migrated cells per HPF, 95% CI = 14.1 to 26.4 migrated cells per 
HPF, P < .001) or lysophosphatidylcholine plus arachidonic acid 
(CDIBA + lysophosphatidylcholine + arachidonic acid vs CDIBA: 
27.9 vs 10.3 migrated cells per HPF, difference = 17.6 migrated 
cells per HPF, 95% CI = 13.6 to 21.6 migrated cells per HPF, P < 
.001) (Figure 2, B). Thus, the ability of MPMEC and 3B-11 vascu-
lar endothelial cells to invade and migrate may be dependent on 
lysophospholipids in addition to the well-characterized arachidonic 
acid pathway.
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Figure  2.  Effects  of  lysophospholipids  on  invasion  and  migration  of 
cPLA2-deficient and CDIBA-treated vascular endothelial cells. cPLA2a
1/1 
(wild type [WT]) and cPLA2a
2/2 (knockout [KO]) murine pulmonary mi-
crovascular endothelial cells (A) or murine vascular endothelial 3B-11 
cells (B) were added to the top chambers of 24-well transwell Boyden 
chamber plates containing 8-µm Matrigel-coated inserts. Fresh medium 
was added to the bottom chambers; vehicle (control) or 2 µM CDIBA 
(3B-11 only) was added to the medium in both chambers with or with-
out 10 µM lysophosphatidylcholine (LPC), 10 µM lysophosphatidic acid 
(LPA), or 10 µM arachidonic acid (AA); and the plates were incubated 
for 24 hours. The inserts were removed and migrated cells on the 
lower surfaces of the filters were stained with DAPI (4′,6-diamidino-2-
phenylindole) and counted in four randomly chosen high-power micro-
scopic fields (HPFs) per sample. Bar graphs plot the mean number of 
migrated cells per HPF for triplicate samples from three independent 
experiments; error bars correspond to 95% confidence intervals. A): *P = 
.004 (Student t test); **P < .001 (analysis of variance [ANOVA]). B): *P < 
.001 (Student t test); **P < .001 (ANOVA). All P values are two-sided.
Differential Effect of cPLA2 Inhibition on Migration of 
Vascular Endothelial and Tumor Cells
To examine whether CDIBA-mediated cPLA2 inhibition also af-
fects the migratory ability of tumor cells, we performed a scratch 
assay for cell migration using 3B-11 and LLC cells. The cells were 
cultured  on  plates  to  70%–80%  confluency,  and  four  parallel 
scratches were created on each plate using a 10-µL pipette tip. The 
cells were treated with DMSO or CDIBA (2 µM) for 24 hours, and 
cells that had migrated into the scratched areas were counted. In 
3B-11 cells, compared with DMSO, CDIBA produced a statisti-
cally  significant  reduction  in  the  number  of  migrated  cells  per 
HPF (CDIBA vs DMSO: 25.8% vs 100%, difference = 74.2%, 
95% CI = 63.2% to 85.1%, P < .001) (Figure 3). By contrast, we 
observed  no  statistically  significant  reduction  in  the  migratory 
ability of lung tumor LLC cells treated with the cPLA2 inhibitor 
(Figure 3). These data suggest that cPLA2 may be more important 
for endothelial cell migration than for tumor cell motility.
Effect of cPLA2 Inhibition on Tubule Formation by 
Vascular Endothelial Cells
One of the initial stages in angiogenesis is the assembly of vascular 
endothelial cells into tubular vessels. To examine whether cPLA2 
plays a role in this process, we performed a capillary-like tubule 
formation  assay.  3B-11  cells  and  HUVEC  were  plated  onto 
Matrigel-coated 24-well plates in medium that contained vehicle 
or CDIBA (2 µM). The cells were incubated at 37°C until tubules 
formed from control cells (6 hours for 3B-11 and 24 hours for 
HUVEC). Tubule formation was then analyzed by light micros-
copy. In 3B-11 cells, treatment with CDIBA reduced tubule forma-
tion by 64% compared with vehicle (average number of tubules per 
HPF, CDIBA vs vehicle: 12 vs 32.6, difference = 20.6, 95% CI = 
17.0 to 24.2, P = .005) (Figure 4). In HUVEC, treatment with 
CDIBA reduced tubule formation by 40% compared with vehicle 
(average number of tubules per HPF, CDIBA vs vehicle: 12.3 vs 
20.3, difference = 8.0, 95% CI = 5.8 to 10.3, P = .009) (Figure 4). 
Thus, these results suggest that cPLA2 may play a pivotal role in 
the formation of a functional vascular network.
Effect of cPLA2 Inhibition on Tumor Growth
We  next  examined  whether  cPLA2  inhibition  is  sufficient  to 
suppress  tumor  growth  in  syngeneic  heterotopic  mouse  tumor 
models of lung cancer (LLC cells) and glioblastoma (GL261 cells). 
cPLA2a
1/1 C57/BL6 mice (n = 6–7 mice per group) received sub-
cutaneous injections of LLC or GL261 tumor cells in the right 
hind  limbs.  Tumor-bearing  mice  were  treated  intraperitoneally 
with CDIBA (0.5 or 1.0 mg per kg body weight) or vehicle once 
daily for five or seven consecutive days. Tumor volume was mon-
itored by external caliper measurements at 48-hour intervals, until 
tumor volumes reached approximately 700 mm
3. Compared with 
mice treated with vehicle, LLC tumor growth in mice treated with 
CDIBA was delayed by 5 days (average number of days to reach 
tumor volume of 700 mm
3, CDIBA vs vehicle: 16.8 vs 11.8, differ-
ence = 5, 95% CI = 3.6 to 6.4, P = .04) (Figure 5, A and B). In the 
GL261 glioma model, the delay in tumor growth was even more 
pronounced in mice treated with CDIBA compared with mice treated 
with  vehicle.  Following  treatment  cessation,  inhibition  of  tumor 
growth was sustained from day 7 to day 9. Furthermore, 2 days after jnci.oxfordjournals.org    JNCI | Articles 1405
the seventh and final treatment, 50% of CDIBA-treated mice exhib-
ited complete tumor regression, and the regressed tumors remained 
undetectable throughout the remainder of the study (Figure 5, C). 
Volume calculations for the remaining tumors revealed that GL261 
tumors  in  CDIBA-treated  mice  were  statistically  significantly 
smaller than those in mice treated with vehicle (mean volume on day 
21, CDIBA vs vehicle: 40.1 vs 247.4 mm
3, difference = 207.3 mm
3, 
95% CI = 20.9 to 293.7 mm
3, P = .021) (Figure 5, D).
To  verify  that  CDIBA  inhibited  the  enzymatic  activity  of 
cPLA2  in  vivo,  we  analyzed  plasma  samples  obtained  from  the 
previously treated LLC tumor–bearing mice before treatment and 
immediately after administration of the final treatment with vehicle 
Figure 3. Differential effect of cPLA2 inhibition on migration of vascular 
endothelial  and  tumor  cells.  A  scratch  assay  for  cell  migration  was 
performed  on  3B-11  or  Lewis  lung  carcinoma  (LLC)  cells  grown  to 
70%–80% confluency. Four parallel wounds were created on each plate 
using a 10-µL pipette tip, and the cells were treated with dimethyl sulf-
oxide (control) or the cPLA2 inhibitor CDIBA (2 µM) for 24 hours. The 
cells were then stained with 1% methylene blue, and cells inside and 
outside of the wound boundaries were counted. Migration is expressed 
as mean cell density within the wound. A) Representative micrographs 
of stained cells (at ×10 magnification). B) Bar graph of the average cell 
density within the wound from three independent experiments; error 
bars  correspond  to  95%  confidence  intervals.  *P  <  .001  (two-sided 
Student t test).
Figure 4. Effect of cPLA2 inhibition on tubule formation by vascular en-
dothelial cells. 3B-11 cells or human umbilical vein endothelial cells 
(HUVEC)  were  cultured  on  Matrigel-coated  24-well  plates  in  the 
absence (control) or presence of 2 µM CDIBA. Capillary tubule forma-
tion was evaluated after 6 (3B-11) or 24 (HUVEC) hours of incubation. 
Tubule  formation  was  quantified  as  the  number  of  tubules  per 
high-power microscopic field (HPF) in four randomly selected HPF per 
sample. A) Representative micrographs of treated cells (at ×20 magnifi-
cation). B) Bar graph of the mean number of tubules per HPF for 3B-11 
and  HUVEC  from  three  independent  experiments;  error  bars  corre-
spond to 95% confidence intervals. Control vs CDIBA: *P = .005 and 
**P = .009 (two-sided Student t test).
or CDIBA. In CDIBA-treated mice, cPLA2 activity was reduced by 
59% after the final treatment compared with cPLA2 activity before 
treatment  initation  (1.4  vs  4.3  µmol/min/mL,  difference  =  2.9 
µmol/min/mL, 95% CI = 2.5 to 3.3 µmol/min/mL, P = .004). By 
contrast, in mice treated with vehicle alone, a statistically signifi-
cant  decrease  in  plasma  cPLA2  activity  was  not  observed  after 
treatment (Figure 5, E). Plasma lysophosphatidic acid levels were 
also measured before treatment and immediately after the final 
treatment.  There  was  no  statistically  significant  difference  in 
plasma  lysophosphatidic  acid  concentration  following  treatment 
with CDIBA as compared with plasma samples obtained before the 1406   Articles | JNCI  Vol. 102, Issue 18  |  September 22, 2010
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Figure 5. Effect of cPLA2 inhibition on tumor growth. Lewis lung carci-
noma (LLC) (A and B) or GL261 cells (C and D) were injected subcuta-
neously into the hind limbs of cPLA2a1/+ C57/BL6 mice. To inhibit cPLA2 
in vivo, approximately 2 weeks after tumor cell injection, mice received 
intraperitoneal injections of vehicle (control) or CDIBA at 0.5 or 1.0 mg 
per kg body weight once per day for five (LLC) or seven (GL261) consec-
utive days (n = 6–7 mice per group). cPLA2 activity was measured by an 
enzymatic activity assay in plasma obtained from LLC tumor–bearing 
mice before treatment initiation and immediately after the final treat-
ment. Tumor volume was measured using an external caliper. A) Mean 
LLC  tumor  volume;  treatment  administered  on  days  1–5.  B)  Mean 
number of days for LLC tumors to reach 700 mm3 in mice treated with 
vehicle and in mice treated with 1.0 mg CDIBA per kg body weight. *P = 
.04 (Student t test). C) Mean GL261 tumor volume; treatment adminis-
tered on days 1–7. Control vs CIBDA: P = .03 (day 9), P = .03 (day 13), 
P = .01 (day 15), P = .01 (day 17), P = .02 (day 19), and P = .02 (day 21) 
(longitudinal analysis of least squares means). D) Mean GL261 tumor 
volume for each treatment group on day 21. *P = .021 (Student t test). 
E) cPLA2 activity in plasma from control and CDIBA-treated mice before 
treatment  initiation  (pre)  and  immediately  after  the  final  treatment 
(post). *P = .004 (analysis of variance). Error bars correspond to 95% 
confidence intervals, and all P values are two-sided.
initiation  of  treatment  (data  not  shown).  Thus,  treatment  with 
CDIBA in vivo inhibited the enzymatic activity of cPLA2 but did 
not affect the circulating plasma levels of lysophosphatidic acid.
Tumor Growth in cPLA2a-Deficient Mice
To further examine the role of cPLA2 in angiogenesis and tumor 
progression, we monitored the growth of tumors in cPLA2a
1/1 and 
cPLA2a
2/2 mice that were injected subcutaneously into the hind 
limb with LLC cells or GL261 cells (n = 6–7 mice per group). 
Tumor volumes were monitored at 48-hour intervals using power 
Doppler sonography until they exceeded a volume of 700 mm
3 or 
a diameter of 15 mm. Despite an initial tumor take rate of 100% 
and progression to tumor volumes in the range of 100–200 mm
3 by 
14 days after tumor cell injection in both groups of mice, complete jnci.oxfordjournals.org    JNCI | Articles 1407
sectioned, and the sections were examined for microvessel density 
by immunohistochemical staining with an antibody against vWF, 
a  known  vascular  endothelial  cell  marker  (Figure  7,  A). 
Immunohistochemical  examination  revealed  that  tumors  from 
cPLA2a
2/2 mice had statistically significant fewer vessels per HPF 
compared  with  tumors  from  wild-type  mice  (mean  number  of 
vessels per HPF, cPLA2a
2/2 vs cPLA2a
1/1: 2.4 vs 5.4, difference = 
3.0 vessels per HPF, 95% CI = 2.7 to 3.2 vessels per HPF, P < 
.001) (Figure 7, A and B). Hematoxylin–eosin staining of tumor 
sections revealed multiple necrotic areas in tumors from cPLA2a
2/2 
mice, but only minimal necrosis in tumors from cPLA2a
1/1 mice, 
spontaneous LLC tumor regression was observed in 50% of the 
cPLA2a
2/2 mice but in none of the cPLA2a
1/1 mice. Furthermore, 
tumor volume measurements from day 16 onward revealed a sta-
tistically  significant  reduction  in  mean  tumor  volume  in  the 
remaining tumors from cPLA2a
2/2 mice compared with tumors 
from cPLA2a
1/1 mice (mean tumor volume on day 16, cPLA2a
2/2 
vs cPLA2a
1/1: 90 vs 518.3 mm
3, difference = 428.3 mm
3, 95% CI = 
223.1 to 633.5 mm
3, P = .047) (Figure 6, A). The effects of cPLA2 
deficiency on tumor growth were even more pronounced in the 
GL261  tumor  model  (Figure  6,  B).  Whereas  cPLA2a
1/1  mice 
exhibited gradual tumor growth progression (tumor take = 100%), 
GL261 tumor formation in cPLA2a
2/2 mice remained undetectable 
1 month after the injection of tumor cells (tumor take = 0%).
Vascularity, Pericyte Coverage, and Necrosis in LLC 
Tumors From cPLA2a
2/2 Mice
To determine the effects of cPLA2 deficiency on tumor vascularity, 
LLC tumors from cPLA2a
1/1 and cPLA2a
2/2 mice were resected 
once  tumors  reached  volumes  of  700  mm
3,  formalin  fixed,  and 
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Figure 6. Tumor growth in cPLA2a-deficient mice. Lewis lung carcinoma 
(LLC) or GL261 cells were injected subcutaneously into the hind limbs 
of cPLA2a1/1 or cPLA2a2/2 C57/BL6 mice (n = 6–7 mice per group). Tumor 
volume was measured using power Doppler sonography at 48-hour 
intervals  beginning  1  week  after  injection  and  ending  when  tumors 
reached a volume of 700 mm3 or a diameter of 15 mm). A) Mean LLC 
tumor  volume  for  cPLA2a1/1  mice  and  for  remaining  tumors  from 
cPLA2a2/2 mice at day 16 after tumor cell injection. *P = .047 (two-sided 
Student t test). B) Mean GL261 tumor volumes. cPLA2a1/1 vs cPLA2a2/2. 
Days 11–39: P < .001 (longitudinal analysis of least squares means). 
Error bars correspond to 95% confidence intervals.
Figure 7. Vascularity and necrosis in tumors from cPLA2a
2/2 mice. Lewis 
lung carcinoma (LLC) cells were injected subcutaneously into the hind 
limbs of cPLA2a
1/1 and cPLA2a
2/2 mice (n = 6–7 mice per group). Once 
the average tumor volume reached approximately 700 mm
3, the mice 
were killed by cervical dislocation and their tumors were resected and 
fixed in 10% formalin. Fixed tumors were then sectioned, and the sec-
tions  were  stained  with  an  antibody  against  von  Willebrand  factor 
(vWF) (an endothelial cell marker) or hematoxylin–eosin. vWF-positive 
vessels were counted with the use of immunofluorescence microscopy. 
A) Representative micrographs of positive anti-vWF staining (green) 
at ×40 magnification in sections of tumors from cPLA2a1/1 (left) and 
cPLA2a2/2 (right) mice.  B) Mean number of  tumor blood vessels per 
high-power microscopic field (HPF) from cPLA2a1/1 and cPLA2a2/2 mice 
(three  mice  per  group;  six  HPFs  per  slide).  Error  bars  correspond 
to  95%  confidence  intervals.  *P  <  .001  (two-sided  Student  t  test). 
C) Representative micrographs of hematoxylin–eosin-stained sections 
of LLC tumors from cPLA2a1/1 (left) and cPLA2a2/2 (right) mice (at ×40 
magnification). Black arrow indicates necrosis.1408   Articles | JNCI  Vol. 102, Issue 18  |  September 22, 2010
suggesting that cPLA2 may be an important factor for tumor for-
mation, growth, and maintenance (Figure 7, C).
To investigate whether cPLA2 is involved in tumor blood vessel 
maturation, LLC tumor sections were co-stained with antibodies 
to vWF and a-SMA or desmin. As two proteins that are expressed 
by pericytes (cells that surround small blood vessels), a-SMA and 
desmin are often used to identify the stage of vascular development 
(40).  Microscopic  assessment  of  a-SMA  immunofluorescence 
revealed substantial pericyte coverage of the tumor vasculature in 
LLC  tumors  from  cPLA2a
1/1  mice,  whereas  in  tumors  from 
cPLA2a
2/2  mice,  vessel-encircling  pericytes  were  undetectable 
(Figure 8, A). Because a-SMA expression may depend on the stage 
of pericyte maturation (40), we also stained tumor sections with an 
antibody against desmin, which is expressed by mature and imma-
ture pericytes (40). Although desmin was detected in tumor vascula-
ture from cPLA2a
1/1 mice, no desmin-positive cells were observed 
within tumor blood vessels from cPLA2a
2/2 mice (Figure 8, B). 
These marked differences in desmin and a-SMA staining suggest 
that, in addition to its role in endothelial cell function, cPLA2 may 
also be required for pericyte recruitment and vessel maturation.
Discussion
Whereas previous studies have shown that cPLA2 and arachidonic 
acid  are  associated  with  tumor  progression,  this  study  provides 
evidence  that  cPLA2  promotes  tumor  angiogenesis  through  a 
lysophospholipid-mediated mechanism. Our data from cell culture 
experiments implicate key regulatory roles for cPLA2 and the lyso-
phospholipids lysophosphatidylcholine and lysophosphatidic acid 
in proliferation and invasive migration of and tubule formation by 
vascular  endothelial  cells.  In  addition,  we  showed  in  a  mouse 
tumor model that, despite expression of cPLA2 in the tumor cells, 
cPLA2 deficiency within the host component resulted in delayed 
tumor growth, impaired tumor vascularization, and decreased 
Figure 8. Pericyte coverage of blood vessels in 
tumors  from  cPLA2a
1/1  and  cPLA2a
2/2  mice. 
Formalin-fixed  Lewis  lung  carcinoma  (LLC) 
tumors  from  cPLA2a
1/1  (upper  rows)  and 
cPLA2a
2/2 (lower rows) mice were sectioned 
and  co-stained  with  antibodies  against  von 
Willebrand  factor  (left  panels)  and  either 
a-smooth muscle actin (middle panels, A) or 
desmin (middle panels, B) and counterstained 
with DAPI (4′,6-diamidino-2-phenylindole). A) 
Representative  micrographs  of  immunofluo-
rescence  staining  for  von  Willebrand  factor 
(green),  a-smooth  muscle  actin  (red),  and 
DAPI  (blue)  in  tumors  from  cPLA2a
1/1  and 
cPLA2a
2/2 mice (at ×40 magnification). Right 
panels present merged immunofluorescence 
staining  of  von  Willebrand  factor  and  cells 
positive for a–smooth muscle actin (yellow). 
B) Representative micrographs of immunoflu-
orescence staining for von Willebrand factor 
(green),  desmin  (red),  and  DAPI  (blue)  in 
tumors  from  cPLA2a
1/1  and  cPLA2a
2/2  mice 
(at ×40 magnification). Right panels present 
merged immunofluorescence staining of von 
Willebrand factor and cells positive for desmin 
(yellow).jnci.oxfordjournals.org    JNCI | Articles 1409
pericyte development in tumor blood vessels. Thus, these clinically 
relevant findings identify cPLA2 and lysophospholipids as important 
molecular targets for angiogenic blockade and anticancer therapy.
Blood vessel formation is a fundamental process that occurs 
during  both  normal  and  pathological  tissue  growth.  In  malig-
nancies such as lung cancer and glioblastoma, vascularization is 
often  excessive  and  associated  with  tumor  progression  (41). 
Multiple antiangiogenic agents have been developed in an effort to 
inhibit  tumor  growth.  However,  although  several  angiogenesis 
inhibitors have produced an enhanced clinical benefit, many of 
these pharmacological agents result in only transitory improve-
ments that are followed by increased tumor resistance (42). Thus, 
the development of novel effective antiangiogenic therapies could 
improve tumor control in treatment-resistant vascularized cancers, 
such as lung carcinoma and glioblastoma. In this study, we identify 
a key regulatory role for cPLA2 in tumor angiogenesis and provide 
evidence that inhibition of cPLA2 activity may prevent the forma-
tion of a functional tumor vascular network.
We found that cPLA2 inhibition with CDIBA provided a statis-
tically significant attenuation of capillary-like tubule formation in 
vitro in two vascular endothelial cell lines (3B-11 and HUVEC). In 
addition, results from a scratch assay revealed that treatment of the 
endothelial cell lines with CDIBA reduced cell migration by 75% 
but  had  no  statistically  significant  effect  on  migration  of  lung 
tumor cells. Thus, these data suggest that cPLA2 contributes to 
both the formation of tubules and the migratory ability of vascular 
endothelial cells during tumor vascularization.
The migration and tubule formation ability of vascular endo-
thelial cells depend on the ability of the vascular endothelium to 
degrade both the basement membrane and the extracellular matrix 
of  the  surrounding  connective  tissue  (41).  In  a  transwell  filter 
assay, we found that cPLA2 inhibition dramatically reduced the 
ability of cultured vascular endothelial cells to degrade a basement 
membrane matrix (ie, solidified Matrigel) and migrate through a 
Matrigel-coated filter. These results suggest that cPLA2 has an 
essential  role  in  the  migratory  function  of  vascular  endothelial 
cells. Because cPLA2 is responsible for the production of the bio-
active lipid mediators lysophosphatidylcholine, arachidonic acid, 
and lysophosphatidic acid, we examined which of these products 
contributes to vascular endothelial cell migration. Although addi-
tion of lysophosphatidylcholine, lysophosphatidic acid, or arachi-
donic  acid  alone  to  the  culture  medium  resulted  in  increased 
migration of cPLA2a
2/2 MPMEC and 3B-11 cells treated with 
CDIBA,  the  most  pronounced  effect  was  observed  with  the   
addition of lysophosphatidylcholine plus lysophosphatidic acid or 
lysophosphatidylcholine plus arachidonic acid. These results indi-
cate that, although arachidonic acid and lysophosphatidic acid 
can regulate endothelial cell migration (25–27,32), the less well 
characterized lysophosphatidylcholine pathway may also play an 
important role in this process.
In addition to endothelial cell migration, tumor vascularization 
requires  the  proliferation  of  endothelial  cell  populations.  To 
examine the effects of CDIBA on cell proliferation, we assessed 
staining with an antibody against Ki-67, a well-known marker of 
proliferation  (43,44),  in  MPMEC,  3B-11,  and  LLC  cells.  The 
number of Ki-67–positive cells was statistically significantly lower 
in MPMEC from cPLA2a
2/2 mice compared with MPMEC from 
cPLA2a
1/1 mice and in 3B-11 cells treated with CDIBA compared 
with 3B-11 cells treated with vehicle. Furthermore, BrdU incorpo-
ration  but  not  metabolic  activity  was  also  reduced  in  CDIBA-
treated 3B-11 cells compared with vehicle-treated cells, suggesting 
that cPLA2 inhibition affects proliferation rather than cell viability. 
LLC tumor cell proliferation, however, remained unchanged by 
cPLA2 inhibition. The addition of lysophosphatidylcholine plus 
arachidonic  acid  to  the  culture  medium  resulted  in  a  modest 
increase  in  Ki-67  staining,  whereas  the  greatest  increase  was 
observed in endothelial cells treated with lysophosphatidylcholine 
plus lysophosphatidic acid. These findings were further supported 
by evidence from primary cultures of MPMEC, in which the most 
pronounced increase in cell proliferation was observed in cPLA2a2/2 
MPMEC treated with the combination of lysophosphatidylcholine 
and lysophosphatidic acid. These data demonstrate a key role 
for cPLA2 in endothelial cell proliferation and indicate that two 
lysophospholipids—lysophosphatidylcholine and lysophosphatidic 
acid—may act as effectors for this stage of angiogenesis.
To examine the role of cPLA2 in tumor growth, we studied 
mouse  tumor  models  of  lung  carcinoma  and  glioblastoma.  We 
found that intraperitoneal injection of CDIBA, a chemical inhib-
itor  of  cPLA2,  into  tumor-bearing  mice  provided  a  statistically 
significant delay in tumor growth in both tumor models. In addi-
tion, in the glioblastoma model, we observed tumor regression 
while the mice were receiving CDIBA. Given the high level of 
vascularity  in  glioblastoma  multiforme  tumors,  this  unexpected 
biological response may be because of impaired blood flow, which 
may have ultimately prevented cancer growth (45–49). Moreover, 
GL261 tumor growth suppression was sustained for several days 
after the cessation of treatment, suggesting that CDIBA exhibits a 
prolonged  pharmacodynamic  effect.  Analysis  of  plasma  samples 
from LLC tumor–bearing mice revealed a statistically significant 
reduction in cPLA2 activity in CDIBA-treated mice compared with 
vehicle-treated  mice,  confirming  previous  reports  of  CDIBA-
dependent inhibition of cPLA2 activity in vivo (36,50–53). However, 
there was no substantial change in plasma lysophosphatidic acid 
concentration. These results indicate that cPLA2 inhibition may 
have a transient effect on lysophosphatidylcholine production, but 
no effect on the circulating plasma levels of lysophosphatidic acid. 
Because lysophosphatidic acid can also be generated independently   
of lysophosphatidylcholine by a variety of other enzymes, including 
phospholipase D, phospholipase A1, and secretory phospholipase 
A2, reduced lysophosphatidylcholine levels do not necessarily cor-
relate with decreased lysophosphatidic acid production (28,54).
Our findings in the mouse models support previous studies that 
showed decreased tumorigenesis in mice genetically deficient in 
cPLA2 (55,56). In the more recent of these studies (56), cPLA2a
2/2 
mice  exhibited  decreased  lung  tumor  metastasis  as  a  result  of 
reduced production of interleukin 6 by the tumors and a decrease 
in the number of macrophages surrounding the tumor. However, 
neither study considered whether tumor blood vessel formation 
was involved in the impairment of tumorigenesis. In this study, we 
analyzed the role of cPLA2 in tumor vascularization in cPLA2a
1/1 
and  cPLA2a
2/2  mice.  In  the  syngeneic  heterotopic  lung  tumor 
model, we observed that tumor volume in cPLA2a
2/2 mice was 
statistically  significantly  lesser  than  that  in  cPLA2a
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Furthermore, we observed spontaneous lung tumor regression in 
50% of the cPLA2a2/2 mice but no such regression in the wild-type 
mice. Upon histological examination of the remaining tumors, we 
observed a stastically significant reduction in the number of blood 
vessels  in  tumors  from  cPLA2a
2/2  mice  compared  with  tumors 
from cPLA2a1/1 mice. Furthermore, immunofluorescence staining 
revealed a striking absence of a-SMA- and desmin-positive peri-
cytes within the tumor vasculature of cPLA2a2/2 mice. Because 
previous  studies  have  shown  that  tumor  pericytes  can  regulate 
vessel integrity, maintenance, and function (40,57–60), the lack of 
desmin and a-SMA staining in the tumor vasculature of cPLA2a2/2 
mice may indicate that cPLA2 is also involved in pericyte recruit-
ment and tumor vessel maturation. In addition, multiple areas of 
necrosis were present in tumors from cPLA2a
2/2 mice, but only 
minimal  necrosis  was  detected  in  lung  tumors  from  cPLA2a1/1 
mice, suggesting that cPLA2 may be necessary for sufficient tumor 
blood flow.
We observed an even greater suppression of tumor growth in 
the  glioblastoma  tumor  model  than  in  the  LLC  tumor  model. 
Following injection of GL261 tumor cells, gradual tumor progres-
sion  occurred  in  cPLA2a
1/1  mice,  whereas  tumor  formation  in 
cPLA2a
2/2 mice remained undetectable up to 1 month after injec-
tion.  These  results  suggest  that  the  presence  of  cPLA2  activity 
within the tumor microenvironment contributes to efficient tumor 
development.
Although  these  results  implicate  a  novel  role  for  cPLA2  in 
tumor angiogenesis, this study is not without limitations. First, we 
used heterotopic model systems to study the effect of cPLA2 on 
tumor growth. Many studies have shown that the growth advan-
tages of the subcutaneous microenvironment may differ from that 
of the original tumor organ site (61,62). Moreover, in the case of 
spontaneous  tumor  metastasis,  orthotopic  injection  is  often 
necessary  to  sufficiently  represent  clinical  cancer  (61).  When 
assessing tumor growth and angiogenesis in the absence of metas-
tasis,  however,  subcutaneous  model  systems  are  routinely  used 
(63–65). Thus, based on work conducted in previous investiga-
tions, and to reduce the morbidity that is associated with ortho-
topic models of lung cancer and glioblastoma (66), we selected 
heterotopic tumor models for our study.
A second experimental challenge was revealed during the im-
munohistochemical examination of pericyte coverage. Because of 
the diverse functions, locations, and maturation stages of pericytes 
within various organs, no universal molecular marker of these cells 
has yet to our knowledge been discovered (40). To address this 
limitation, we used two different markers—a-SMA and desmin—
to  identify  both  mature  and  immature  pericytes.  However,  we 
acknowledge that some perivascular cells may not have been rec-
ognized by the antibodies to a-SMA and desmin because of tissue 
specificity or the angiogenic stage of the tumor vasculature.
Together, our findings indicate that cPLA2 and lysophospholipids 
have a key role in the invasive migration, proliferation, and capillary-
like tubule formation of vascular endothelial cells. In addition, we 
found that in mouse tumor models, cPLA2 deficiency within the 
host component resulted in delayed tumor growth and impaired 
tumor vascularization. Thus, these data identify cPLA2 as an impor-
tant factor in tumor angiogenesis and suggest that cPLA2 may be a 
novel molecular target for antiangiogenesis cancer therapy.
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